Grassley Reminds Pharma CEOs How Much Drug List Prices Matter During Hearing; We Need More Drug Price Transparency

WASHINGTON – Republican Iowa Sen. Chuck Grassley reminded seven pharmaceutical company executives that drug list prices matter to patients during a Senate Finance Committee hearing on drug prices Thursday.

“For a patient taking a drug that has no competition, the list price becomes very important,” committee chairman Grassley said, according to NPR. “I’ve heard about people skipping doses of their prescription drugs to make them last until the next paycheck.”

Grassley and the committee’s ranking member, Democratic Oregon Sen. Ron Wyden, questioned executives from companies including Johnson & Johnson, AstraZeneca and Pfizer at Thursday’s hearing.

The drug company CEOs discussed their companies’ investments in research and development and price distortion due to pharmacy benefit managers (PBMs), but commitments to lowering drugs were “noticeably absent,” reported CNBC.

“Last year, Janssen invested $8.4 billion globally in research and development, making Janssen one of the top research and development investors in any industry anywhere in the world,” said Jennifer Taubert, worldwide chairwoman of pharmaceuticals for Johnson & Johnson, which owns Janssen, according to NPR.



Big Tech is using NewsGuard to censor us severely reducing our revenue. You can support our mission of truthful reporting by making a contribution. Honest journalism is incredibly important to our democracy; we refuse to let Silicon Valley crush us into just another regurgitated, propaganda driven, echo-chamber of lamestream media and we need your support. You can also help by signing up for our featured story emails.
 

Wyden and Grassley continued to press the executives for high list prices, even as the CEOs responded by saying list price does not always equate to what patients pay.

“Prescription drugs did not become outrageously expensive by accident,” Wyden said at the hearing, according to NPR. “Drug prices are astronomically high because that’s where pharmaceutical companies and their investors want them.”

The executives also addressed a Trump administration proposal to bring big changes to the way PBMs work by negotiating secret rebates to set drug prices. The administration wants to ban those rebates and “force pharmacy benefit managers to instead negotiate discounts upfront so that people will get the discounts at the pharmacy counter even if they haven’t yet met their deductible,” reported NPR.

“We will try to move every single penny to the patients,” Albert Bourla, CEO of Pfizer, said of the rebates.

Other companies represented at the hearing included AbbVie, Bristol-Myers Squibb, Merck and Sanofi. AbbVie faced scrutiny in 2018 for allegedly providing illegal kickbacks to doctors and patients to boost drug sales.

Follow Evie on Twitter @eviefordham.

Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to corrections@publishedreporter.com and cite any sources if available. Thank you. (Policy)